Vimarsana
Biggest News Aggregation in the World

Page 18 - Diagnostics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diagnostics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diagnostics Inc Today - Breaking & Trending Today

Polymyxin Resistance Testing Market Advances Toward US$ 222.5 Million by 2033-FMI Study - Vimarsana News

Polymyxin Resistance Testing Market Advances Toward US$ 222.5 Million by 2033-FMI Study

Polymyxin Resistance Testing MarketIn 2023, the polymyxin resistance testing market size is projected to be worth US$ 122.0 million. The market is projected to expand at a 6.2% CAGR during the forecast period, reaching US$ 222.5 million by 2033. Serious infections caused by Gram-negative bacteria that are resistant...

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro - Vimarsana News

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Co-Diagnostics, Inc. announced that it has submitted its Co-Dx?? PCR COVID-19 test with Co-Dx PCR Pro?? instrument for review by the U.S. Food and Drug Administration for Emergency Use Authorization...

In Vitro Diagnostic Tests Market Report, with Profiles of 300+ Companies and Detail on the Top 40 - Vimarsana News

In Vitro Diagnostic Tests Market Report, with Profiles of 300+ Companies and Detail on the Top 40

/PRNewswire/ -- The "Worldwide Market for In Vitro Diagnostic Tests, 16th Edition" report has been added to ResearchAndMarkets.com's offering. The 16th edition...

Antimicrobial Susceptibility Testing Market : Emerging Technologies and Trends | CAGR of 5.8% from 2 - Vimarsana News

Antimicrobial Susceptibility Testing Market : Emerging Technologies and Trends | CAGR of 5.8% from 2

According to the report published by Allied Market Research, the global antimicrobial susceptibility testing market generated $3.04 billion in 2020, and is anticipated to reach $4.73 billion by 2030, manifesting a CAGR of 5.8% from 2021 to 2030. The report offers an in-depth analysis of the market size, emerging and...

DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer - Vimarsana News

DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer

/PRNewswire-PRWeb/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced...